Infant Protection Against Respiratory Syncytial Virus (RSV) by Maternal RSV Vaccination or Receipt of Nirsevimab, and Intent for Nirsevimab Receipt, United States

Principal Investigator(s):  View help for Principal Investigator(s) United States Department of Health and Human Services. Centers for Disease Control and Prevention; Pregnancy & Vaccination

Version:  View help for Version V1

Name File Type Size Last Modified
Infant Protection Against Respiratory Syncytial Virus (RSV) by Maternal RSV Vacc.csv text/csv 5.5 KB 01/09/2026 11:05:AM
Infant Protection Against Respiratory Syncytial Virus (RSV) by Maternal RSV Vaccination or Receipt o.pdf application/pdf 412.2 KB 01/08/2026 10:23:AM

Project Citation: 

United States Department of Health and Human Services. Centers for Disease Control and Prevention, and Pregnancy & Vaccination. Infant Protection Against Respiratory Syncytial Virus (RSV) by Maternal RSV Vaccination or Receipt of Nirsevimab, and Intent for Nirsevimab Receipt, United States. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2026-01-09. https://doi.org/10.3886/E242834V1

Project Description

Project Title:  View help for Project Title Infant Protection Against Respiratory Syncytial Virus (RSV) by Maternal RSV Vaccination or Receipt of Nirsevimab, and Intent for Nirsevimab Receipt, United States
Summary:  View help for Summary Infant Protection Against RSV by Maternal RSV Vaccination or Receipt of Nirsevimab and Intent for Nirsevimab Receipt, Reported by Females Aged 18-49 Years Who Have an Infant <8 Months During the RSV Season (born since April 1, 2024) Monthly estimates of infant protection against RSV by maternal RSV vaccination or receipt of nirsevimab, as well as intent for nirsevimab receipt, were calculated using data from the from the National Immunization Survey–Adult COVID Module (NIS–ACM). (https://www.cdc.gov/nis/about/index.html). Data were reported by adult females aged 18-49 years with infants under the age of 8 months during the RSV season (born since April 1, 2024). The NIS–ACM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older. All estimates are based upon parent-reported receipt of nirsevimab. Read less
Original Distribution URL:  View help for Original Distribution URL https://data.cdc.gov/Pregnancy-Vaccination/Infant-Protection-Against-Respiratory-Syncytial-Vi/vdz4-qrri/about_data

Scope of Project

Subject Terms:  View help for Subject Terms nis-acm; vsd; iis; iqvia; nis-flu; rsv vaccination
Collection Notes:  View help for Collection Notes (Downloaded 1/8/2026)


Related Publications

Download this project

Published Versions

V1 [2026-01-09]

Export Metadata

Dublin Core

DDI 2.5

Report a Problem

Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.

This material is distributed exactly as received from the data depositor. ICPSR has not reviewed, checked, or processed this material. For additional information about the study, please contact the investigator(s) directly. If you have questions about the accessibility of materials distributed by ICPSR or require further assistance, please visit ICPSR's Accessibility Center.